The Medicines and Healthcare products Regulatory Agency (MHRA) has announced strengthened addiction warnings for a range of commonly prescribed medicines, including gabapentinoids, benzodiazepines, and Z-drugs. This decision follows a recent safety review aimed at highlighting the addictive nature of these medications, which are used to treat conditions such as pain, anxiety, and insomnia.

Patient information leaflets accompanying these drugs will now prominently feature the warning: 'may cause addiction, dependence, and withdrawal reactions'. Furthermore, the updated leaflets will provide clearer definitions of dependence and addiction, offer improved guidance on how to safely taper and stop medication use, and encourage open conversations between patients and healthcare professionals throughout their treatment journey.

Gabapentinoids, such as gabapentin and pregabalin, are primarily prescribed for nerve pain and epilepsy, though they are also used 'off-label' for other conditions. NHS figures for 2022/2023 revealed that approximately 4.5 million people in England were prescribed gabapentinoids. These drugs affect GABA neurotransmitters in the brain, producing pain relief, reducing anxiety, and inducing numbing and sedation. It is estimated that around 800,000 individuals in the UK take pregabalin daily, with a notable percentage expressing concerns about physical dependence and the difficulty of discontinuation. Some users may even resort to purchasing additional tablets online or from street dealers due to increasing dosage requirements.

Beyond changes to packaging and product information, the Commission on Human Medicines (CHM), as part of the review, put forward additional warnings against using these medicines with opioids or alcohol, and advised against sharing medication with others.

Benzodiazepines, often referred to as 'benzos', are typically prescribed as a short-term solution (2-4 weeks) for severe, disabling anxiety or insomnia during a crisis. NHS-issued benzodiazepines include diazepam (the most used in the UK, also for alcohol withdrawal), lorazepam and temazepam (used before surgical procedures), and chlordiazepoxide (for alcohol withdrawal). Clobazam and clonazepam are also benzodiazepines but are specifically used to manage epilepsy and seizures. Alprazolam, known as Xanax, is only available via private prescription in the UK.

Z-drugs are a class of non-benzodiazepine medications prescribed for the short-term treatment of severe insomnia. Their name derives from the fact that many initial drugs in this class begin with the letter 'Z'. Current NHS-issued Z-drugs include zopiclone (Zimovane, Imovane) and zolpidem (Ambien, Stilnoct). Zaleplon (Sonata, Starnoc) ceased being prescribed in the UK in 2004.

Dr. Alison Cave, MHRA Chief Safety Officer, emphasized that addiction and dependency can affect anyone using these medicines, even when taken as directed. She stated that strengthening these warnings will help both patients and healthcare professionals better understand the risks. While these medicines remain valuable treatments, it is crucial for patients to have the necessary information for safe use. Dr. Cave advised patients with questions about their medication or side effects to consult a healthcare professional and cautioned against discontinuing medication without medical advice, as this could trigger withdrawal symptoms.